GLAXO · Healthcare
Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹957 cr for July to September 2023, — on the year and +25.6% on the quarter.
Operating profit (EBITDA) was ₹289 cr, a margin of 30.2%, — on the year and +1,130 bps on the quarter.
Net profit was ₹218 cr, — on the year and +65.2% on the quarter, with earnings per share of ₹12.84.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹957 cr | ₹805 cr | ₹930 cr | ₹815 cr | ₹1,011 cr | ₹949 cr | ₹974 cr | ₹805 cr | ₹980 cr | ₹1,041 cr | ₹995 cr | ₹938 cr |
| YoY | — | — | — | +7% | +6% | +18% | +5% | −1% | −3% | +10% | +2% | +17% |
| EBITDA margin | 30.2% | 27.1% | 27.6% | 28.3% | 31.8% | 30.8% | 34.2% | 31.2% | 34.3% | 35.6% | 35.3% | 31.6% |
| Other income, % of PBT | 9% | −208% | 12% | 14% | 11% | 11% | 11% | 16% | 10% | 13% | 10% | 14% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% |
| Net profit | ₹218 cr | ₹46.0 cr | ₹194 cr | ₹182 cr | ₹252 cr | ₹230 cr | ₹263 cr | ₹205 cr | ₹257 cr | ₹296 cr | ₹278 cr | ₹237 cr |
| YoY | — | — | — | +38% | +16% | +400% | +36% | +13% | +2% | +29% | +6% | +16% |
| Core profit YoY | — | — | — | +68% | +13% | +37% | +33% | +10% | +4% | +28% | +6% | +18% |
| EPS | ₹12.84 | ₹2.70 | ₹11.48 | ₹10.76 | ₹14.91 | ₹13.57 | ₹15.52 | ₹12.10 | ₹15.20 | ₹17.45 | ₹16.40 | ₹14.00 |
| Flags | · | · | · | ✓ | ✓ | 1 | 1 | ✓ | ✓ | ✓ | 1 | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹957 cr (— on the year) and net profit of ₹218 cr (— on the year) for July to September 2023.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.